SCHEMBL1789784

SCHEMBL1789784

NC(=O)c1cccc(-c2ccc(CN[C@@H]3Cc4ccc(F)cc4C3)c(F)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.50
OPRD1 P41143 6/20 0.50
OPRK1 P41145 6/20 0.50
DPP4 P27487 1/20 0.46
CTSC P53634 4/20 0.42
CTSK P43235 3/20 0.42
PRMT5 O14744 1/20 0.39
ERN1 O75460 1/20 0.39
PARP1 P09874 1/20 0.39
FAAH O00519 2/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
KCNH2 Q12809 1/20 0.39
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
TDP2 O95551 1/20 0.38
CLK1 P49759 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1784107 1.00 OPRM1 (0.50) OPRM1OPRD1OPRK1DPP4CTSC
SCHEMBL14292991 1.00 OPRM1 (0.50) OPRM1OPRD1OPRK1DPP4CTSC
Hydrochloric Acid SCHEMBL3339935 0.99 OPRM1 (0.49) OPRM1OPRD1OPRK1DPP4CTSC
Hydrochloric Acid SCHEMBL16194927 0.99 OPRM1 (0.49) OPRM1OPRD1OPRK1DPP4CTSC
SCHEMBL12651471 0.92 OPRM1 (0.58) OPRM1OPRD1OPRK1DPP4CTSC
Hydrochloric Acid SCHEMBL3342684 0.91 OPRM1 (0.57) OPRM1OPRD1OPRK1DPP4CTSC
SCHEMBL12651505 0.88 OPRM1 (0.58) OPRM1OPRD1OPRK1DPP4PRMT5
SCHEMBL12651264 0.88 OPRM1 (0.58) OPRM1OPRD1OPRK1DPP4PRMT5
SCHEMBL12651508 0.88 OPRM1 (0.58) OPRM1OPRD1OPRK1DPP4PRMT5
Hydrochloric Acid SCHEMBL16194773 0.87 OPRM1 (0.58) OPRM1OPRD1OPRK1DPP4PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-8822518-B2 Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction GLAXOSMITHKLINE LLC (US) 2014-09-02 US disclosed
US-8633175-B2 Compounds as antagonists or inverse agonists at opioid receptors GLAXOSMITHKLINE LLC (US) 2014-01-21 US disclosed
US-8633175-B2 Compounds as antagonists or inverse agonists at opioid receptors GLAXOSMITHKLINE LLC (US) 2014-01-21 US disclosed
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2011-05-26 US disclosed
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2011-05-26 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 OPRM1 4/4885OPRD1 2/4885OPRK1 3/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.